Navigation Links
Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
Date:8/27/2008

SEATTLE, Aug. 27 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that executives will present a corporate update at the upcoming Morgan Stanley Global Healthcare Unplugged Conference to be held at the Grand Hyatt New York on Sept. 9, 2008. Dr. Peter Thompson, president, chief executive officer and chairman, and Dr. Scott C. Stromatt, newly appointed senior vice president and chief medical officer, are scheduled to present on Tuesday, Sept. 9 at 4:30 p.m. EDT. The presentation will be available via audio webcast on Trubion's investor website at investors.trubion.com.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience.
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
4. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
5. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
6. Trubion Announces Presentations at April/May Investor Conferences
7. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Raleigh, NC (PRWEB) June 19, 2013 ... and eclinical commerce network for clinical trials, today ... technology at DIA 2013 (booth #2000) in Boston, ... is the industry’s first and only fully configurable, ... technology, ClinPay®, the flagship module within Clinverse’s eClinical ...
(Date:6/19/2013)... 19, 2013  Continuing its long history of proven ... Beckman Coulter , Inc. announces the U.S. Food and ... AccuTnI+3 troponin I assay for use on its Access ... on Beckman Coulter,s troponin I test for ... the proven performance to continue providing dependability to laboratories ...
(Date:6/19/2013)... 2013 Today DuPont Executive Vice President ... become leaders in the greatest challenge facing our time ... 2050. Borel spoke at the International Food ... about urgent need for students to contribute their time ... sustainable and reached in collaboration with others. , “Food ...
(Date:6/19/2013)... Bloomington, Indiana (PRWEB) June 19, 2013 ... Valentine joined the speaking faculty at 2013’s BioLogistics ... , The conference, coordinated by Cold Chain IQ ... surrounding biologics. This “complexity” is, in part, attributed ... medicine. , “Implicit within these trends is ...
Breaking Biology Technology:Clinverse, Inc. Exhibiting and Showcasing Its Technology at DIA 2013 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 3DuPont Leader Calls for New Generation of Food Visionaries to Fight Hunger 2BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2
... Chindex International,Inc. (Nasdaq: CHDX ), an independent ... products in the People,s,Republic of China, today announced ... ended March 31, 2008., For the 2008 ... $130.1,million, an increase of 23% over the prior ...
... Takes Prominent Position and ... WEST SENECA, N.Y., June 11 Palladian Muscular Skeletal,Health ... a high-profile presence at a leading healthcare event -- ... June,18 to Friday, June 20, 2008., "We have ...
... Rosetta Genomics has Signed a Binding Term Sheet to Acquire Parkway ... ... Significantly Streamline the Development and Commercialization of Rosetta Genomics, microRNA-based ... Needs to Market and Sell its microRNA-based Tests in the U.S. and ...
Cached Biology Technology:Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 2Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 3Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 4Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 5Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 6Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 7Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 8Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 9Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 10Palladian Muscular Skeletal Health (formerly Prism Health Networks) to Promote Collaborative, Expanded Practice Model at Major Insurance Conference in June 2Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 2Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 3Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 4Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 5Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 6
(Date:6/19/2013)... June 19, 2013 A study published in the ... the first report of an oral probiotic supplement significantly ... , The lead author on the study, Mitchell ... Presentation Prize from the New York Academy of Sciences ... week,s Probiotics, Prebiotics, and the Host Microbiome: The ...
(Date:6/19/2013)... the Marine Biological Laboratory (MBL), Woods Hole, Massachusetts, ... by the American Society for Microbiology (ASM). ... and the scientists who worked there that have ... microbiology. A ceremony unveiling the plaque that ... June 22, 2013, at 4:30 pm in the ...
(Date:6/19/2013)... A team of researchers at the University of ... outer coating of HIV, that could be potential ... avoid generating resistance. These new agents are quite ... The research was published in the June 2013 ... Chemotherapy . , The first of many probable ...
Breaking Biology News(10 mins):Study shows probiotic Lactobacillus reuteri NCIMB 30242 significantly increased vitamin D levels 2Microbial diversity course designated as a 'Milestones in Microbiology' site 2HIV-derived antibacterial shows promise against drug-resistant bacteria 2
... under scrutiny lately due to adverse cardiovascular side-effects stemming ... models, researchers reveal another adverse effect of Celecoxib; this ... independent of the COX-2 enzyme. Satpal Singh ... rate of Drosophila, a good model for human cardiac ...
... friends used to think he was eccentric, crawling like ... Pennsylvania, hauling dental tools and a jack hammer. ... gotten over it, and are congratulating him on receiving ... Society, presented at the Geological Society of Americas recent ...
... of medical and scientific books and journals, was ... content is immediately available on www.springerlink.com ... and more than 22,000 eBooks. Beginning with the ... purchase Humana Press journals through Springer. All issues ...
Cached Biology News:Academy volunteer wins national paleontology award 2Humana Press journals now available on SpringerLink 2
... intensely fluorescent and highly photostable FluoSpheres ... in a variety of applications requiring ... signal. Unfortunately, protein- and other macromolecule-labeled ... cause them to bind to non-target ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... Description: Proteinase K is a highly active ... of applications purified from the fungus T. album. ... group of N-substituted hydrophobic aliphatic and aromatic amino ... serine protease. Proteinase K is useful in purifying ...
...
Biology Products: